Bangalore, India – February 11, 2026 – OneSource Speciality Pharma Limited has received approval from the Saudi Food and Drug Authority (SFDA) to commercialize a generic version of Ozempic (semaglutide) in Saudi Arabia, the company announced today. The approval enables OneSource to partner with Hikma Pharmaceuticals PLC (Hikma) for exclusive commercialization throughout the Middle East and North Africa (MENA) region.
The approval marks a significant entry for OneSource, a contract development and manufacturing organization (CDMO), into the Kingdom of Saudi Arabia, which is considered a key market for glucagon-like peptide-1 (GLP-1) therapies. The collaboration with Hikma, the largest pharmaceutical company in MENA based on sales, is intended to broaden access to more affordable alternatives to the branded medication.
Semaglutide is the active pharmaceutical ingredient in both Ozempic, used to treat type 2 diabetes, and Wegovy, prescribed for weight management, both marketed by Novo Nordisk. A key patent protecting semaglutide is set to expire in several markets in March, potentially opening the door for wider generic competition.
Under the terms of the exclusive agreement, OneSource will be responsible for the manufacturing and supply of semaglutide from its integrated biologics and drug-device combination facility located in Bengaluru, India. Hikma will then utilize its established commercial infrastructure and relationships within the region to distribute the product through both private and institutional channels.
“We are extremely excited to secure SFDA approval for semaglutide in Saudi Arabia, one of the largest GLP-1 market globally with significant long-term potential,” said Neeraj Sharma, Chief Executive Officer and Managing Director of OneSource Specialty Pharma Limited. “We are confident that collaborating with Hikma, the largest pharmaceutical company in the MENA region by sales, will give us a strong platform to scale access to this important therapy across both private and institutional customers.”
The partnership comes as demand for GLP-1 receptor agonists continues to rise globally, driven by increasing rates of type 2 diabetes and obesity. The availability of a generic version of semaglutide in the MENA region is expected to address unmet needs and improve affordability for patients.
